Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations

Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allo- wing long-term control of its clinical signs and symp- toms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belong- ing to special populations are scarce. This observatio- nal, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treat- ment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as can- cers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological dis- orders. Patients achieved a significant improvement in both physician-assessed and patient-reported out- comes after 16 weeks of treatment, with a continu- ous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.